S100B is a calcium-binding protein mainly concentrated in astrocytes in the nervous system. Its levels in biological fluids are recognized as a reliable biomarker of active neural distress, and more recently, mounting evidence points to S100B as a Damage-Associated Molecular Pattern molecule, which, at high concentration, triggers tissue reactions to damage. S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease. In addition, in experimental models of diseases such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, multiple sclerosis, traumatic and vascular acute neural injury, epilepsy, and inflammatory bowel disease, alteration of S100B levels correlates with the occurrence of clinical and/or toxic parameters. In general, overexpression/administration of S100B worsens the clinical presentation, whereas deletion/inactivation of the protein contributes to the amelioration of the symptoms. Thus, the S100B protein may be proposed as a common pathogenic factor in different disorders, sharing different symptoms and etiologies but appearing to share some common pathogenic processes reasonably attributable to neuroinflammation.

Michetti, F., Clementi, M. E., Di Liddo, R., Valeriani, F., Ria, F., Rende, M., Di Sante, G., Romano Spica, V., The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2023; 24 (11): N/A-N/A. [doi:10.3390/ijms24119605] [https://hdl.handle.net/10807/302185]

The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker

Michetti, Fabrizio;Ria, Francesco;Di Sante, Gabriele;
2023

Abstract

S100B is a calcium-binding protein mainly concentrated in astrocytes in the nervous system. Its levels in biological fluids are recognized as a reliable biomarker of active neural distress, and more recently, mounting evidence points to S100B as a Damage-Associated Molecular Pattern molecule, which, at high concentration, triggers tissue reactions to damage. S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease. In addition, in experimental models of diseases such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, multiple sclerosis, traumatic and vascular acute neural injury, epilepsy, and inflammatory bowel disease, alteration of S100B levels correlates with the occurrence of clinical and/or toxic parameters. In general, overexpression/administration of S100B worsens the clinical presentation, whereas deletion/inactivation of the protein contributes to the amelioration of the symptoms. Thus, the S100B protein may be proposed as a common pathogenic factor in different disorders, sharing different symptoms and etiologies but appearing to share some common pathogenic processes reasonably attributable to neuroinflammation.
2023
AREA06 - SCIENZE MEDICHE
Pubblicazione su rivista con Impact Factor
Inglese
Articolo in rivista
Inglese
pathogenic factor
S100B protein
Settore MEDS-02/A - Patologia generale
Multidisciplinary Digital Publishing Institute (MDPI)
24
11
2023
N/A
N/A
9605
Goal 3: Good health and well-being
info:eu-repo/semantics/article
Michetti, F., Clementi, M. E., Di Liddo, R., Valeriani, F., Ria, F., Rende, M., Di Sante, G., Romano Spica, V., The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2023; 24 (11): N/A-N/A. [doi:10.3390/ijms24119605] [https://hdl.handle.net/10807/302185]
open
262
Michetti, Fabrizio; Clementi, M. E.; Di Liddo, R.; Valeriani, F.; Ria, Francesco; Rende, M.; Di Sante, Gabriele; Romano Spica, V.
8
art_per_29
03. Contributo in rivista::Articolo in rivista, Nota a sentenza
File in questo prodotto:
File Dimensione Formato  
ijms-24-09605.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 925.6 kB
Formato Adobe PDF
925.6 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/302185
Citazioni
  • ???jsp.display-item.citation.pmc??? 73
  • Scopus 104
  • ???jsp.display-item.citation.isi??? 99
social impact